Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 358 (20), 2117-26

Cardiac Troponin and Outcome in Acute Heart Failure

Affiliations

Cardiac Troponin and Outcome in Acute Heart Failure

W Frank Peacock 4th et al. N Engl J Med.

Abstract

Background: Cardiac troponin provides diagnostic and prognostic information in acute coronary syndromes, but its role in acute decompensated heart failure is unclear. The purpose of our study was to describe the association between elevated cardiac troponin levels and adverse events in hospitalized patients with acute decompensated heart failure.

Methods: We analyzed hospitalizations for acute decompensated heart failure between October 2001 and January 2004 that were recorded in the Acute Decompensated Heart Failure National Registry (ADHERE). Entry criteria included a troponin level that was obtained at the time of hospitalization in patients with a serum creatinine level of less than 2.0 mg per deciliter (177 micromol per liter). A positive troponin test was defined as a cardiac troponin I level of 1.0 microg per liter or higher or a cardiac troponin T level of 0.1 microg per liter or higher.

Results: Troponin was measured at the time of admission in 84,872 of 105,388 patients (80.5%) who were hospitalized for acute decompensated heart failure. Of these patients, 67,924 had a creatinine level of less than 2.0 mg per deciliter. Cardiac troponin I was measured in 61,379 patients, and cardiac troponin T in 7880 patients (both proteins were measured in 1335 patients). Overall, 4240 patients (6.2%) were positive for troponin. Patients who were positive for troponin had lower systolic blood pressure on admission, a lower ejection fraction, and higher in-hospital mortality (8.0% vs. 2.7%, P<0.001) than those who were negative for troponin. The adjusted odds ratio for death in the group of patients with a positive troponin test was 2.55 (95% confidence interval, 2.24 to 2.89; P<0.001 by the Wald test).

Conclusions: In patients with acute decompensated heart failure, a positive cardiac troponin test is associated with higher in-hospital mortality, independently of other predictive variables. (ClinicalTrials.gov number, NCT00366639 [ClinicalTrials.gov].).

Similar articles

See all similar articles

Cited by 143 articles

  • Troponins in Heart Failure - a Perpetual Challenge.
    Gherasim L. Gherasim L. Maedica (Buchar). 2019 Dec;14(4):371-377. doi: 10.26574/maedica.2019.14.4.371. Maedica (Buchar). 2019. PMID: 32153668 Free PMC article.
  • Monitoring of biomarkers in heart failure.
    Spoletini I, Coats AJS, Senni M, Rosano GMC. Spoletini I, et al. Eur Heart J Suppl. 2019 Dec;21(Suppl M):M5-M8. doi: 10.1093/eurheartj/suz215. Epub 2019 Dec 31. Eur Heart J Suppl. 2019. PMID: 31908607 Free PMC article.
  • Clinical Impact of High-Sensitivity Cardiac Troponin T on the Chronic Phase of Stable Angina after a Successful Initial Percutaneous Coronary Intervention.
    Okamoto H, Kume T, Koyama T, Tamada T, Yamada R, Neishi Y, Uemura S. Okamoto H, et al. Acta Cardiol Sin. 2020 Jan;36(1):16-23. doi: 10.6515/ACS.202001_36(1).20190704C. Acta Cardiol Sin. 2020. PMID: 31903004 Free PMC article.
  • Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T).
    Alvi RM, Frigault MJ, Fradley MG, Jain MD, Mahmood SS, Awadalla M, Lee DH, Zlotoff DA, Zhang L, Drobni ZD, Hassan MZO, Bassily E, Rhea I, Ismail-Khan R, Mulligan CP, Banerji D, Lazaryan A, Shah BD, Rokicki A, Raje N, Chavez JC, Abramson J, Locke FL, Neilan TG. Alvi RM, et al. J Am Coll Cardiol. 2019 Dec 24;74(25):3099-3108. doi: 10.1016/j.jacc.2019.10.038. J Am Coll Cardiol. 2019. PMID: 31856966
  • Effect of a Strategy of Comprehensive Vasodilation vs Usual Care on Mortality and Heart Failure Rehospitalization Among Patients With Acute Heart Failure: The GALACTIC Randomized Clinical Trial.
    Kozhuharov N, Goudev A, Flores D, Maeder MT, Walter J, Shrestha S, Gualandro DM, de Oliveira Junior MT, Sabti Z, Müller B, Noveanu M, Socrates T, Ziller R, Bayés-Genís A, Sionis A, Simon P, Michou E, Gujer S, Gori T, Wenzel P, Pfister O, Conen D, Kapos I, Kobza R, Rickli H, Breidthardt T, Münzel T, Erne P, Mueller C; GALACTIC Investigators, Mueller C, Erne P, Müller B, Rickli H, Maeder M, Tavares de Oliveira M Jr, Münzel T, Bayés-Genís A, Sionis A, Goudev A, Dimov B, Hartwiger S, Arenja N, Glatz B, Herr N, Isenrich R, Mosimann T, Twerenbold R, Boeddinghaus J, Nestelberger T, Puelacher C, Freese M, Vögele J, Meissner K, Martin J, Strebel I, Wussler D, Schumacher C, Osswald S, Vogt F, Hilti J, Barata S, Schneider D, Schwarz J, Fitze B, Hartwiger S, Arenja N, Glatz B, Herr N, Isenrich R, Mosimann T, Twerenbold R, Boeddinghaus J, Nestelberger T, Puelacher C, Freese M, Vögele J, Meissner K, Martin J, Strebel I, Wussler D, Schumacher C, Osswald S, Vogt F, Hilti J, Barata S, Schneider D, Schwarz J, Fitze B, Arenja N, Rentsch K, Bossa A, Jallad S, Soeiro A, Georgiev D, Jansen T, Gebel G, Bossard M, Christ M. Kozhuharov N, et al. JAMA. 2019 Dec 17;322(23):2292-2302. doi: 10.1001/jama.2019.18598. JAMA. 2019. PMID: 31846016 Clinical Trial.
See all "Cited by" articles

Publication types

Associated data

LinkOut - more resources

Feedback